BioPartner UK is your point of contact for the UK delegation to Cologne. Visit us in the Exhibition Hall to find out more about doing business with UK companies, and to meet those in the UK delegation.
Biopartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.
Biopartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.
Lin BatesonExecutive Director
Miss Caroline WrightExhibition Assistant
Mr Luke LloydMarketing Communications Executive
Censo Biotechnologies Ltd
Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.
The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body.
By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population.
Mr Aidan CourtneyChief Executive Officer
Dr Julie HolderHead of Innovation
Clinical Network Services
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.
CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.
BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.
CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Further information about CNS and its intelligent development services can be found at www.clinical.net.au
Paul CroninDirector of Business Development
Russell NealManaging Director
Dr Andrew CarnegieBusiness Development Manager
Datatrial is a clinical biometrics and technology organization specializing in complete study delivery; from our flexible and intuitive platform of technologies to our services and consulting. We offer a full range of services including Data Management, Statistics and Medical Writing.
With headquarters in Newcastle upon Tyne, UK and offices in Boston MA and BioHub at Alderley Park, UK we are very able to support global clinical development programs. Since 1999, we have been serving the pharmaceutical community through our commitment to service and quality in every aspect of the work that we do. With involvement in over 300 clinical trials, across 25 therapeutic areas and with extensive oncology experience we will work with you to develop a study plan that best fits your needs.
Our innovative nowEDC™ solution will allow you to deliver data capture, verification and validation, query management, data extract, IWRS and real-time reporting in one integrated system. nowEDC is easy-to-use, fully validated and is highly configurable. The flexible aspects of nowEDC also make it a natural fit for handling both complex trial designs as well as adaptive clinical trials. We are a service-driven company; our customers and the clinical development programmes that we support are important to us.
Our goal is to meet timelines, exceed expectations through our proactive approach, and be responsive to and collaborative with our customers. Communication, service and quality are critical to a successful clinical study, while always keeping the patient in mind.
Dr Emma BanksCEO
Miss Amy WrightStrategic Services Manager
Dora Wirth (Languages) Ltd
Beatriz Puche Lopez
ERA Consulting has served the biopharmaceutical industry for over 28 years, providing regulatory, strategic and technical guidance for the development of medicinal agents (>450 to date), including gene and cell therapies, recombinant protein/antibody therapeutics, vaccines and small molecules.
Our specialised international team of 32 full-time professionals includes consultants from biotech, pharma, biomanufacturing, regulatory and academic scientific backgrounds to provide experienced support from product inception through development to commercialisation.
Dr Tara SandersonDirector of Regulatory Affairs - CMC Biologics
Mr Adam LevyGroup Manager, Business Development
Fusion Antibodies Ltd
Fusion Antibodies is a high quality European CRO that offers a range of fee-for-service, royalty free technology services covering all stages of therapeutic development of Biopharmaceutical drugs- from discovery/preclinical to cell line development and clinical supply.
Our clients are global Japan, USA & Europe and include Academic, Biotech’s and most of the top 10 pharmaceutical companies.
Four antibodies which have been produced using Fusion Antibodies technologies are currently being progressed through clinical development.
At BioEurope, Fusion Antibodies showcases our next generation CDRx Antibody Humanization Platform (www.fusionantibodies.com/humanization) converting Mouse, Rat, Rabbit and Llama antibodies into high expressing, functional humanized antibody lead drug candidates.
CDRx platform Humanization Key points
• Next generation in silico Antibody Humanization platform
• Improvements over traditional CDR grafting methods
• T-Cell epitope screening and avoidance included in the design stage
• 3D structural predictions included
• No Royalty Fee
• 15 years experience of Antibody drug development
• Humanized variants that can be named with the suffix –“tuzumab” under the International Nonproprietary Names (INN) Programme as governed by the WHO
• Humanized variants selected for manufacturability and expression
• Stable cell expression with CHOvolution cell line capable of up to 7g per litre
• 4 humanized antibodies entering the clinic in 16/17
• More than 60 humanization projects completed worldwide for large pharma, mid-size and biotechs in the past 5 years in Japan, USA & Europe.
We look to partner with companies interested in developing high quality antibody drugs. We also offer a range of cell line development services (https://www.fusionantibodies.com/CLD) and have the associated expertise and partners to deliver a high quality CHO cell line expression for your protein of interest from proof-of-concept to cGMP. Fusion Antibodies also specialize in high quality monoclonal antibodies (particularly those which are difficult to produce), Antibody Sequencing and other Antibody engineering project (scFv, F(ab), Bi-Specifics). We have the capacity to act as a 1-stop shop, guiding your project from discovery to validation in the clinic.
Summary Fusion Antibodies services
cGMP ready CHO cell line development
Manufacture of Biopharmaceuticals for Phase I, II and III clinical studies
With 15+ years of experience in the antibody drug research industry and >60 antibody humanization projects with multiple candidates now in the clinic.
Fusion Antibodies is the 1st choice for accelerating your antibody research towards the clinic.
Let us make your idea a clinical ready drug Asset!
Dr Paul KerrManaging Director
Glythera is an early-stage Biotechnology company focused on the development of next-generation biologics, principally Antibody Drug Conjugates (ADCs) for cancer indications.
The Company’s ADC pipeline is based on an industry-leading, proprietary conjugation platform, ‘PermaLink’, which enables ADCs with higher therapeutic indices – a clear market need in fighting difficult-to-treat tumours. PermaLink is a cysteine-specific, non-maleimide approach that demonstrates significantly improved ADC conjugation stability and improved product homogeneity resulting in improved TI and patient safety profiles. Through PermaLink, Glythera is able to combine novel, highly potent toxins that induce apoptosis with novel antibodies that target cancer-specific antigens, especially those that are highly overexpressed in solid tumours.
The company is currently using its proprietary technology and access to a broad range of toxin payloads to develop a portfolio of class leading ADCs. Glythera is funded by IP Group and the North East Technology Fund and is based in Newcastle Upon Tyne, England.
Dr David SimpsonCEO
Dr Ian EvettsChief Business Officer
IDACO Consulting Ltd
IDACO supports academics, TTOs, start-ups, SMEs and corporate organisations looking for R&D support, outsourcing options and partnering opportunities.
• Strategic pharmaceutical and pre-clinical consulting services.
• Due diligence, evaluation and de-risking of R&D.
• Advice and support on out-sourcing strategies - looking for timely and cost-effective solutions.
• Scouting the academic network to identify new opportunities for pharmaceutical and medical device companies.
• Business development support for organisations wanting to access the academic, outsourcing or commercial networks.
• Oversight and project management of outsourced CMC and preclinical projects.
Mr Ian CoxDirector
Medherant develops transdermal patches using its novel Tepi-Patch® technology. Its unique solvent-free adhesive allows direct dissolution of a wide range of drugs achieving high drug loading, sustained strong drug release and excellent patch adhesion. TepiPatch® can improve upon existing patches or allow development of patches for hard to formulate drugs.